Top Banner
Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
22

Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Dec 19, 2015

Download

Documents

Erik Perkins
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Chapter 3

Lifespan Considerations

Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 2: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Drug Therapy During Pregnancy

Drugs cross the placenta by diffusion Factors affecting safety:

Drug properties Fetal gestational age Maternal factors

FDA has implemented pregnancy safety categories

2Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 3: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

3Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 4: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Classroom Response Question

When teaching a pregnant woman about the use of drugs during pregnancy, which statement will the nurse include?

A.Exposure of the fetus to drugs is most detrimental during the second trimester of pregnancy.

B.Pregnant women must never take drugs to control high blood pressure.

C.Drug transfer to the fetus is most likely to occur during the last trimester of pregnancy.

D.The fetus is at greatest risk for drug-induced developmental defects during the second trimester of pregnancy.

4Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 5: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Drug Therapy During Breastfeeding

Breastfed infants are at risk for exposure to drugs consumed by the mother

Consider risk-to-benefit ratio

5Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 6: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

6Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 7: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Absorption Gastric pH less acidic Gastric emptying slowed Intramuscular absorption faster and irregular

Neonatal and Pediatric Considerations: Pharmacokinetics

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 7

Page 8: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Distribution Greater total body water means lower fat content Decreased level of protein binding Immature blood-brain barrier—more drugs enter the brain

Neonatal and Pediatric Considerations: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 8

Page 9: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Metabolism Liver immature, does not produce enough microsomal enzymes Older children may have increased metabolism, requiring higher

doses than infants Other factors

Neonatal and Pediatric Considerations: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 9

Page 10: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Excretion Kidney immaturity affects glomerular filtration rate and tubular

secretion Decreased perfusion rate of the kidneys may reduce excretion of

drugs

Neonatal and Pediatric Considerations: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 10

Page 11: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Skin is thin and permeable Stomach lacks acid to kill bacteria Lungs have weaker mucus barriers Body temperatures less well regulated, and dehydration

occurs easily Liver and kidneys are immature, impairing drug

metabolism and excretion

Factors Affecting Pediatric Drug Dosages

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 11

Page 12: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Body surface area method Uses the West nomogram

Always use weight in kilograms, not pounds Body weight dosage calculations

Uses mg/kg

Methods of Dosage Calculation for Pediatric Patients

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 12

Page 13: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

13Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 14: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Classroom Response Question

When administering medications to pediatric patients, the nurse understands that the dosage calculations for pediatric patients are different than for adults because pediatric patients

A. are more likely to develop edema.

B. have more stomach acid.

C. have skin that is less permeable.

D. have immature liver and kidney function, resulting in impaired drug metabolism and excretion.

14Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Page 15: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Elderly: older than age 65 High use of medications Polypharmacy Noncompliance, nonadherence Increased incidence of chronic illnesses Sensory and motor deficits

Considerations for Elderly Patients

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 15

Page 16: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 16

Page 17: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Absorption Gastric pH less acidic Gastric emptying slowed Movement through GI tract slowed Blood flow to GI tract reduced Use of laxatives may accelerate GI motility

The Elderly: Pharmacokinetics

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 17

Page 18: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Distribution Lower total body water percentages Increased fat content Decreased production of proteins by the liver, resulting in

decreased protein binding of drugs (and increased circulation of free drugs)

The Elderly: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 18

Page 19: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Metabolism Aging liver produces fewer microsomal enzymes, affecting drug

metabolism Reduced blood flow to the liver

The Elderly: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 19

Page 20: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Excretion Decreased glomerular filtration rate Decreased number of intact nephrons

The Elderly: Pharmacokinetics (cont’d)

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 20

Page 21: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Analgesics, including NSAIDs and opioids Anticoagulants Anticholinergics Antidepressants Antihypertensives Cardiac glycosides (digoxin) Sedatives and hypnotics, CNS depressants Thiazide diuretics

The Elderly:Problematic Medications

Copyright © 2014 by Mosby, an imprint of Elsevier Inc. 21

Page 22: Chapter 3 Lifespan Considerations Copyright © 2014 by Mosby, an imprint of Elsevier Inc.

Classroom Response Question

Which does the nurse identify as a pharmacokinetic change that occurs in the elderly?

A.Gastric pH is more acidic

B.Fat content is decreased because of increased lean body mass

C.Increased production of proteins by the liver

D.The number of intact nephrons is decreased

22Copyright © 2014 by Mosby, an imprint of Elsevier Inc.